COPAN ITALIA SPA v. PURITAN MEDICAL PRODUCTS COMPANY LLC

CourtDistrict Court, D. Maine
DecidedNovember 4, 2019
Docket1:18-cv-00218
StatusUnknown

This text of COPAN ITALIA SPA v. PURITAN MEDICAL PRODUCTS COMPANY LLC (COPAN ITALIA SPA v. PURITAN MEDICAL PRODUCTS COMPANY LLC) is published on Counsel Stack Legal Research, covering District Court, D. Maine primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
COPAN ITALIA SPA v. PURITAN MEDICAL PRODUCTS COMPANY LLC, (D. Me. 2019).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MAINE

COPAN ITALIA S.P.A., et al., ) ) Plaintiffs, ) ) v. ) 1:18-cv-00218-JDL ) PURITAN MEDICAL PRODUCTS ) COMPANY LLC, et al., ) ) Defendants. )

CLAIM CONSTRUCTION ORDER Copan Italia S.p.A. and Copan Diagnostics, Inc. (collectively, “Copan”) bring this patent infringement suit against Puritan Medical Products Company LLC, Puritan Diagnostics LLC, Hardwood Products Company LP, and Hardwood Products Company LLC (collectively, “Puritan”). Because the parties request construction of the preambles and thirteen claim terms in the patents-in-suit, see ECF No. 129 at Page ID 3348−49, the Court held a Markman claim construction hearing on June 26, 2019. See generally Markman v. Westview Instruments, Inc., 517 U.S. 370 (1996). I. FACTUAL BACKGROUND The five patents-in-suit—Patent No. 8,114,027 (“the ‘027 Patent”), Patent No. 8,317,728 (“the ‘728 Patent”), Patent No. 8,979,784 (“the ‘784 Patent”), Patent No. 9,011,358 (“the ‘358 Patent”), and Patent No. 9,173,779 (“the ‘779 Patent”)—relate to a flocked swab device and a method for using flocked swabs to collect, transport, and release biological specimen samples for analysis. All five patents are related, as they all descend from the same patent application and share a common specification.1 The industry predecessor of Copan’s flocked swab was a fiber swab similar in

construction to a Q-tip: a small rod with a wad of fibers wrapped around the tip. Copan asserts that it identified several problems with using fiber swabs to collect biological specimens, including that “on average only about 40% of the liquid specimen collected” could be recovered from the fiber swab for analysis. ‘027 Patent, ECF No. 72-1 at Page ID 768. In response to these problems, Copan developed its flocked swab. Instead of wrapping a wad of fibers around the tip of a rod, Copan used a process known as electrostatic flocking to cover the tip of the rod with fibers. Id.

Electrostatic flocking consists of placing a rod with adhesive on the tip in an electrostatic field and charging both the rod and the fibers, causing the fibers to fly towards the rod and adhere to the tip. Copan claims that a flocked swab “is capable of releasing about 90% of the absorbed specimen” for analysis, in contrast to the fiber swab’s 40% average release rate. Id. at Page ID 769. II. LEGAL ANALYSIS

A. Claim Construction Standards “[T]he claims of a patent define the invention to which the patentee is entitled the right to exclude.” Phillips v. AWH Corp., 415 F.3d 1303, 1312 (Fed. Cir. 2005). The construction of patent claims is a question of law which is “exclusively within the province of the court.” Markman, 517 U.S. at 372, 384. “In determining the proper

1 A specification is a written description of the invention claimed by a patent. See 35 U.S.C.A. § 112 (West 2019); construction of a claim,” a court “look[s] first to the intrinsic evidence of record, i.e., the patent itself, including the claims, the specification and, if in evidence, the prosecution history.” Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed.

Cir. 1996). Courts may also consult extrinsic evidence, “which consists of all evidence external to the patent and prosecution history, including expert and inventor testimony, dictionaries, and learned treatises.” Phillips, 415 F.3d at 1317 (quotation marks omitted). But “such evidence is generally of less significance than the intrinsic record.” Endo Pharm. Inc. v. Actavis LLC, 922 F.3d 1365, 1371 (Fed. Cir. 2019) (quoting Wi-LAN, Inc. v. Apple Inc., 811 F.3d 455, 462 (Fed. Cir. 2016)). “[C]laim construction must begin with the words of the claims themselves.” Id.

at 1370 (quoting Amgen Inc. v. Hoechst Marion Roussel, Inc., 457 F.3d 1293, 1301 (Fed. Cir. 2006)). The terms within a claim are generally given their “ordinary and customary meaning,” which “is the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention, i.e., as of the effective filing date of the patent application.” Phillips, 415 F.3d at 1313. “[T]he person of ordinary skill in the art is deemed to read the claim term not only in the context of

the particular claim in which the disputed term appears, but in the context of the entire patent, including the specification.” Id. Additionally, where, as here, “multiple patents derive from the same parent application and share many common terms, [a court] must interpret the claims consistently across all asserted patents.” Samsung Elecs. Co. v. Elm 3DS Innovations, LLC, 925 F.3d 1373, 1378 (Fed. Cir. 2019) (quotation marks omitted). Though the general rule is that claim terms are given their ordinary meaning, courts may construe a claim term more narrowly than its ordinary meaning in two circumstances: “1) when a patentee sets out a definition and acts as [its] own

lexicographer, or 2) when the patentee disavows the full scope of a claim term either in the specification or during prosecution.” Aventis Pharma S.A. v. Hospira, Inc., 675 F.3d 1324, 1330 (Fed. Cir. 2012). A patentee acts as its own lexicographer if it “‘clearly set[s] forth a definition of the disputed claim term’ other than [the term’s] plain and ordinary meaning.” Thorner v. Sony Comput. Entm’t Am. LLC, 669 F.3d 1362, 1365 (Fed. Cir. 2012) (quoting CCS Fitness, Inc. v. Brunswick Corp., 288 F.3d 1359, 1366 (Fed. Cir. 2002)). A patentee disavows the full scope of a claim term if the

specification or prosecution history “makes clear that the invention does not include a particular feature,” even if the language of the claims otherwise “might be considered broad enough to encompass the feature in question.” Id. at 1366 (quoting SciMed Life Sys., Inc. v. Advanced Cardiovascular Sys., Inc., 242 F.3d 1337, 1341 (Fed. Cir. 2001)). B. Analysis

1. Defining a Person of Ordinary Skill in the Art As discussed above, the “ordinary and customary meaning” of a claim term is “the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention.” Phillips, 415 F.3d at 1313. The parties dispute how a “person of ordinary skill in the art” should be defined in the context of the five patents-in-suit. Copan argues that the patents-in-suit involve two pertinent arts: clinical microbiology, and flocked fiber and textiles arts. Copan asserts that a person of ordinary skill in clinical microbiology has at least a bachelor’s degree in biology or comparable science, as well as two years of practical experience in biological specimen collection and analysis. Copan further asserts that a person of ordinary skill in the

flocked fiber and textiles arts has either four years of experience in fiber science or a bachelor’s degree in chemistry or physics and two years of experience related to fiber science. Puritan proposes a broader, simpler definition, asserting that the pertinent art is any field that would give an artisan general knowledge of flocking techniques and capillarity.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Marrin v. Griffin
599 F.3d 1290 (Federal Circuit, 2010)
Graham v. John Deere Co. of Kansas City
383 U.S. 1 (Supreme Court, 1966)
American Medical Systems, Inc. v. Biolitec, Inc.
618 F.3d 1354 (Federal Circuit, 2010)
Invitrogen Corp. v. Biocrest Manufacturing, l.p.
424 F.3d 1374 (Federal Circuit, 2005)
Merck & Co. v. Teva Pharmaceuticals USA, Inc.
395 F.3d 1364 (Federal Circuit, 2005)
Versa Corporation v. Ag-Bag International Limited
392 F.3d 1325 (Federal Circuit, 2004)
Microsoft Corp. v. i4i Ltd. Partnership
131 S. Ct. 2238 (Supreme Court, 2011)
Thorner v. Sony Computer Entertainment America LLC
669 F.3d 1362 (Federal Circuit, 2012)
Aventis Pharma S.A. v. Hospira, Inc.
675 F.3d 1324 (Federal Circuit, 2012)
Vitronics Corporation v. Conceptronic, Inc.
90 F.3d 1576 (Federal Circuit, 1996)
In Re Montgomery
677 F.3d 1375 (Federal Circuit, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
COPAN ITALIA SPA v. PURITAN MEDICAL PRODUCTS COMPANY LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/copan-italia-spa-v-puritan-medical-products-company-llc-med-2019.